|
| 36857755 | Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. | | 2023 |
| 36322819 | AKT supports the metabolic fitness of multiple myeloma cells by restricting FOXO activity. | Blood advances | 2023 |
| 37756524 | Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS. | | 2023 |
| 37728879 | Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL. | | 2023 |
| 37883186 | BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions. | | 2023 |
| 38052037 | Three Years Maintenance with VRD in Multiple Myeloma: Results of Total Therapy IIIB with a 15-Year Follow Up. | | 2023 |
| 37282609 | Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma. | | 2023 |
| 37468042 | Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines. | | 2023 |
| 37206288 | Variability of definition of high-risk multiple myeloma across phase III clinical trials. | | 2023 |
| 37386588 | A gene signature can predict risk of MGUS progressing to multiple myeloma. | | 2023 |
| 36737587 | Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma. | | 2023 |
| 35881476 | CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. | Journal of Clinical Investigation | 2022 |
| 36018590 | Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma. | JAMA network open | 2022 |
| 33572851 | Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression. | Cancers | 2021 |
| 34061780 | TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies. | Journal of Clinical Investigation | 2021 |
| 33894670 | PHF19 inhibition as a therapeutic target in multiple myeloma. | Current Research in Translational Medicine | 2021 |
| 30279229 | Gene Expression Profiling Reveals Aberrant T-cell Marker Expression on Tumor Cells of Waldenström's Macroglobulinemia. | Clinical Cancer Research | 2019 |
| 27694925 | Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. | Leukemia | 2017 |
| 28400617 | NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma. | Leukemia | 2017 |
| 26220195 | Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression. | Genes Chromosomes and Cancer | 2015 |
| 25640885 | Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma. | Leukemia | 2015 |
| 25061178 | CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease. | Blood | 2014 |
| 24144643 | Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). | Blood | 2014 |
| 24885236 | Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use. | BMC Medical Genomics | 2014 |
| 23372742 | Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels. | PLoS ONE | 2013 |
| 23647456 | TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity. | Br J Haematol | 2013 |
| 23456977 | Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease. | American Journal of Hematology | 2013 |
| 22180482 | Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. | American Journal of Clinical Pathology | 2012 |
| 22855579 | Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1. | Clinical Cancer Research | 2012 |
| 22508408 | Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols. | Leukemia | 2012 |
| 22927484 | Developing and validating continuous genomic signatures in randomized clinical trials for predictive medicine. | Clin Cancer Res | 2012 |
| 22496154 | Prediction of cytogenetic abnormalities with gene expression profiles. | Blood | 2012 |
| 22726547 | Proteasome inhibitors and bone disease. | Seminars in Hematology | 2012 |
| 22726541 | Proteasome inhibitors: introduction. | Seminars in Hematology | 2012 |
| 22419581 | Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. | Haematologica | 2012 |
| 22072558 | An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification. | Blood | 2012 |
| 21732484 | Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone. | Stem Cells | 2011 |
| 22369035 | Maximum predictive power of the microarray-based models for clinical outcomes is limited by correlation between endpoint and gene expression profile. | BMC Genomics | 2011 |
| 21171821 | Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103. | Cytotherapy | 2011 |
| 20884712 | Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. | Haematologica | 2011 |
| 21478911 | Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells. | Oncogene | 2011 |
| 20945320 | International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols. | Cancer | 2011 |
| 21074193 | Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. | J Urol | 2011 |
| 21292777 | Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. | Blood | 2011 |
| 20438295 | Expression of multiple myeloma associated markers in bone marrow spicules using a novel immunohistochemical technique. | Biotechnic and Histochemistry | 2011 |
| 21889435 | Ribosomal protein metallopanstimulin-1 impairs multiple myeloma CAG cells growth and inhibits fibroblast growth factor receptor 3. | Clinical Lymphoma, Myeloma and Leukemia | 2011 |
| 21628408 | Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. | Blood | 2011 |
| 22002477 | The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma. | | 2011 |
| 21715687 | CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. | J Immunol | 2011 |
| 20093236 | Clinical, immunophenotypic, and genetic characterization of small lymphocyte-like plasma cell myeloma: a potential mimic of mature B-cell lymphoma. | American Journal of Clinical Pathology | 2010 |